Supplementary Figure 2: CFSE-labelled Mel-CV and MM200 cells treated with vemurafenib (3 µM
for 36 hours were added along with a blocking antibody against CD47 (B6H12.2, 10 µg/ml) to cultures of macrophages that were labelled with PKH26. Two hours later, non-adherent cells were washed away, and the cultures were examined using a fluorescence microscope.
The phagocytosis index was calculated as the number of phagocytized CFSE + cells per 100 macrophages (n = 3, mean ± S.E.M.; Student's t-test, *P < 0.05). for a further 16 hours. Total RNAs were subjected to qPCR analysis of CD47 mRNA expression. The relative abundance of CD47 mRNA in cells transfected with the control siRNA was arbitrarily designated as 1 (n = 3, mean ± S.E.M.). (C) Mel-RM cells were transfected with the control or Sp1 siRNA. Twenty-four hours later, cells were treated trametinib (1 µM) for a further 16 hours. Total RNAs were subjected to qPCR analysis of CD47 mRNA expression. The relative abundance of CD47 mRNA in cells transfected with the control siRNA was arbitrarily designated as 1 (n = 3, mean ± S.E.M.). (D) MM200 (left) and Mel-RM (right) cells stably overexpressing NRF-1 were introduced with the control siRNA or the combination of ERK1 and ERK2 siRNAs. Twenty-four hours later, whole cell lysates were subjected to Western blot analysis. Data shown are representative of three individual experiments.
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